Accordingly, the avoidance of severe anemia in these high-risk SAH individuals, particularly during the first 2 weeks after SAH, by utilizing a more liberal RBCT strategy than currently practiced in the majority of intensive care units (RBCT at Hb decrease < 7.0 g/dL) might be worthwhile. This evidence concerns the gene GSTM1 and anemia.